Brain+ (BRAINP) Investor Update summary

Product Launch, Solution, and Roadmap

• Launch of CST Assistant/Ayla as a Class 1 medical device in the U.K. is imminent, with a comprehensive product roadmap for 2025, including digital-first, scalable dementia care solutions and future modules like remote monitoring and expanded therapy.

• The platform offers 150+ validated CST sessions, adaptable content, and supports both in-person and virtual delivery, covering the patient journey from pre- to post-diagnosis.

• Integration with electronic patient records, automation of workflows, and use of data analytics and AI are central to scaling, standardizing, and improving therapy efficacy.

• Regulatory validation, NHS procurement platform listing, and positive usability studies support market entry and confirm product-market fit.

• The platform is co-developed with global CST experts and praised for usability and impact by clinicians and users.

Market Opportunity and Positioning

• Dementia is the second leading cause of death globally, with 139 million projected cases by 2050 and global health expenditure reaching €9.1 trillion.

• Diagnosis can take up to a year, with only 31% of diagnosed patients referred for CST due to barriers like long waitlists, lack of standardization, and workforce shortages.

• The digital CST solution is positioned as more effective and scalable than drug and non-drug alternatives, with no side effects and strong clinical evidence.

• The platform addresses major barriers in dementia care, enabling earlier intervention, broader access, and seamless integration into care pathways.

• CST is recommended by NICE, adopted in 39 countries, and delivers a 6-month delay in cognitive decline, improved communication, and quality of life.

Commercial Strategy and Financial Projections

• SaaS-based business model with tiered annual subscriptions, targeting health systems, care homes, and insurance markets, focusing initially on NHS sites in the U.K.

• Year one revenue projection is GBP 0.9 million from 50 sites, scaling to GBP 6.2 million by year four (500 sites), and GBP 62.5 million by year eight (5,000 sites), with ARR targets of €1M by 2025 and €3.5M by year three.

• Pricing is set at GBP 156/£156.15 per patient per year, significantly lower than the average annual dementia care cost of GBP 36,000/£32,250 per patient in the UK.

• Growth assumptions include 440% site penetration increase from 2025-2027, 98% retention rate, and potential for contract uplifts with new product releases.

• Expansion into care home and international markets is anticipated, with further upside not fully factored into current projections.